Helixmith to start gene, cell therapy CDMO business next year

Park Yoon-gyun and Minu Kim 입력 2021. 9. 16. 13:12
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

Helixmith, a gene therapy company in Korea, will make a foray into the contract development and manufacturing organization (CDMO) market for gene and cellular therapy products next year, with a focus on the development of CAR-T therapies for local and global biotech firm in the early stages.

The company’s vision is to become a bio platform company dedicated to solutions related to almost every stage of a gene's life cycle based on its gene therapy development knowhow, Yu Seung-shin, Co-CEO of Helixmith, said at a press conference held on Wednesday.

Helixmith on Monday opened a gene and cell therapy plant for CDMO business.

The company expects more than 10 billion won ($8.55 million) in annual sales from CDMO business two to three years after its launch. Helixmith has identified some 40 firms as potential customers, including Cartexell, the company’s subsidiary for CAR-T therapy development.

Regarding the ongoing clinical trial of Engensis, the company’s investigational plasmid-based gene therapy that targets DPN, a complication of diabetes, Helixmith said it will complete all pivotal Phase 3 trials by 2023 and file a biologics license application with the FDA.

Engensis demonstrated efficacy in a 12-month Phase 3-1b study of 101 DPN patients after primary endpoints were not met in a nine-month Phase 3-1 study of 500 patients.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지

이 기사에 대해 어떻게 생각하시나요?